Aneeqa Zafar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aneeqa Zafar has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Aaron Rosenberg
1 shared publication- Abdul Wahab
Universitas Gadjah Mada
1 shared publication - Alfred Chung
University of California San Francisco, San Francisco, California, United States
1 shared publication Amber Tang
1 shared publicationBenjamin Moskoff
1 shared publicationBipul Baibhav
Rochester General Hospital, Rochester, NY, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 284-292
Utilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases
Introduction: Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS. Case Presentation: We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up. Conclusion: These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.
- 1 January 2026
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 19 (1) , 284-292
Open AccessUtilization and Outcomes of High-Dose Methotrexate in CNS Lymphoma Patients on Hemodialysis: A Report of 2 Cases
Introduction: Patients with end-stage renal disease (ESRD) usually do not receive high-dose methotrexate (HDMTX) therapy due to concerns for increased risk for adverse effects, including bone marrow suppression and mucositis. HDMTX therapy is the standard of care for management of CNS lymphoma, both primary and secondary as well as for managing post-transplant lymphoproliferative disorders involving the CNS. Case Presentation: We report the outcomes of 2 patients with primary CNSL lymphoma on HD who received HDMTX with different dosing strategies. Both patients tolerated treatment well and continue to do well at follow-up. Conclusion: These approaches have not been studied in ESRD, and there is growing interest in developing innovative strategies that enable safe HDMTX administration in patients with ESRD undergoing hemodialysis.
- Open Access
- 18 August 2025
- Published by Elsevier in Current Problems in Cancer: Case Reports
- Vol. 19
Casting a wide net for anemia in advanced prostate cancer: A case series
- 18 August 2025
- Published by Elsevier in Current Problems in Cancer: Case Reports
- Vol. 19
Open AccessCasting a wide net for anemia in advanced prostate cancer: A case series
- Open Access
- 26 May 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (8) , 504.e1-504.e7
Intensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma
- 26 May 2023
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 29 (8) , 504.e1-504.e7
Open AccessIntensity of Cyclophosphamide-Based Bridging Therapy Before Chimeric Antigen Receptor T Cell Therapy in Myeloma
- Open Access
- 1 April 2020
- Published by Wiley in Clinical Case Reports
- Vol. 8 (4) , 658-660
A presumed case of Darbepoetin-induced myocardial infarction in the patient with MDS-RARS
Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin-stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.
- 1 April 2020
- Published by Wiley in Clinical Case Reports
- Vol. 8 (4) , 658-660
Open AccessA presumed case of Darbepoetin-induced myocardial infarction in the patient with MDS-RARS
Our case is only the 2nd such reported case of atherothrombosis from ESAs and highlights the increased risk of cardiovascular events in patients receiving erythropoietin-stimulating agents specially patients with underlying MDS where targeting a lower hemoglobin goal and optimizing other cardiovascular risk factors might be beneficial in preventing future cardiovascular mortality.